Research programme: cancer immunotherapies - OncoQR/TYG Oncology

Next Previous
Drug Profile

Research programme: cancer immunotherapies - OncoQR/TYG Oncology

Alternative Names: OQR 100; OQR 200; TYG 100

Latest Information Update: 18 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoQR
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Gastric cancer; Oesophageal cancer; Pancreatic cancer

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Pancreatic cancer

Most Recent Events

  • 11 Mar 2016 TYG 100 is available for licensing as of 11 Mar 2016. http://www.tyg-oncology.com/
  • 11 Mar 2016 Immunogenicity, pharmacodynamics and safety data from a preclinical study in Pancreatic cancer released by TYG Oncology
  • 11 Mar 2016 TYG 100 and S-TIR™ technology platform licensed to TYG Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top